These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7789488)

  • 1. Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease.
    Ström K; Boman G; Pehrsson K; Alton M; Singer J; Rydström PO; Uddenfeldt M; Ericsson CH; Ostholm B; Mörlin C
    Eur Respir J; 1995 Mar; 8(3):425-9. PubMed ID: 7789488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in day and night time oxygenation with protriptyline in patients with chronic obstructive lung disease.
    Sériès F; Cormier Y; La Forge J
    Thorax; 1989 Apr; 44(4):275-9. PubMed ID: 2763229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sleep quality, carbon dioxide responsiveness and hypoxaemic patterns in nocturnal hypoxaemia due to chronic obstructive pulmonary disease (COPD) without daytime hypoxaemia.
    Sandek K; Andersson T; Bratel T; Hellström G; Lagerstrand L
    Respir Med; 1999 Feb; 93(2):79-87. PubMed ID: 10464857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of protriptyline on diurnal and nocturnal oxygenation in patients with chronic obstructive pulmonary disease.
    Sériès F; Cormier Y
    Ann Intern Med; 1990 Oct; 113(7):507-11. PubMed ID: 2393207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study.
    Górecka D; Sliwiński P; Pałasiewicz G; Pachocki R; Zieliński J;
    Respiration; 2003; 70(3):275-83. PubMed ID: 12915747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for nocturnal hypoxaemia (mean SaO2 < 90%) in normoxic and mildly hypoxic patients with COPD.
    Vos PJ; Folgering HT; van Herwaarden CL
    Eur Respir J; 1995 Jan; 8(1):74-7. PubMed ID: 7744197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of protriptyline on day and night time oxygenation in patients with chronic obstructive pulmonary disease].
    Lin CC
    J Formos Med Assoc; 1993 Dec; 92 Suppl 4():S232-6. PubMed ID: 7910081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One year treatment with almitrine improves hypoxaemia but does not increase pulmonary artery pressure in COPD patients.
    Weitzenblum E; Schrijen F; Apprill M; Prefaut C; Yernault JC
    Eur Respir J; 1991 Nov; 4(10):1215-22. PubMed ID: 1804669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chlormadinone acetate, acetazolamide and oxygen on awake and asleep gas exchange in patients with chronic obstructive pulmonary disease (COPD).
    Vos PJ; Folgering HT; de Boo TM; Lemmens WJ; van Herwaarden CL
    Eur Respir J; 1994 May; 7(5):850-5. PubMed ID: 7519567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment with low dose almitrine bismesylate in hypoxaemic chronic obstructive airways disease.
    Bardsley PA; Howard P; Tang O; Empey D; Harrison B; Peake MD; O'Reilly J; Riordan JF; Wilkinson J; Arnaud F
    Eur Respir J; 1992 Oct; 5(9):1054-61. PubMed ID: 1426214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral almitrine in treatment of acute respiratory failure and cor pulmonale in patients with an exacerbation of chronic obstructive airways disease.
    Bardsley PA; Tweney J; Morgan N; Howard P
    Thorax; 1991 Jul; 46(7):493-8. PubMed ID: 1908604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment.
    Bratel T; Wennlund A; Carlström K
    Respir Med; 2000 Dec; 94(12):1221-8. PubMed ID: 11192959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nocturnal hypoxaemia in chronic obstructive pulmonary disease.
    Stradling JR; Lane DJ
    Clin Sci (Lond); 1983 Feb; 64(2):213-22. PubMed ID: 6681599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of protriptyline for respiratory failure in patients with chronic airflow limitation.
    Carroll N; Parker RA; Branthwaite MA
    Eur Respir J; 1990 Jul; 3(7):746-51. PubMed ID: 2124540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep related O2 desaturation in COPD patients with normoxaemia and mild hypoxyaemia.
    Resta O; Foschino-Barbaro MP; Talamo S; Nocerino MC; Stefano A; Corvaglia G
    Boll Soc Ital Biol Sper; 1998; 74(9-10):91-8. PubMed ID: 10904558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease.
    Winkelmann BR; Kullmer TH; Kneissl DG; Trenk D; Kronenberger H
    Chest; 1994 May; 105(5):1383-91. PubMed ID: 8181324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nocturnal oxygen saturation in advanced chronic obstructive pulmonary disease after a moderate dose of ethanol.
    Brander PE; Kuitunen T; Salmi T; Partinen M
    Eur Respir J; 1992 Mar; 5(3):308-12. PubMed ID: 1572443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of protriptyline in obstructive sleep apnea.
    Brownell LG; Perez-Padilla R; West P; Kryger MH
    Bull Eur Physiopathol Respir; 1983; 19(6):621-4. PubMed ID: 6360257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of protriptyline in patients with chronic obstructive pulmonary disease.
    Sériès F; Marc I; Cormier Y; La Forge J
    Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1487-90. PubMed ID: 8503560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sleep-related oxygen desaturation and daytime pulmonary haemodynamics in COPD patients.
    Levi-Valensi P; Weitzenblum E; Rida Z; Aubry P; Braghiroli A; Donner C; Aprill M; Zielinski J; Würtemberger G
    Eur Respir J; 1992 Mar; 5(3):301-7. PubMed ID: 1572442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.